Parathyroid hormone (1-36) - Novartis
Latest Information Update: 09 Aug 2002
At a glance
- Originator Novartis
- Mechanism of Action Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 11 Jul 1997 New profile
- 11 Jul 1997 Preclinical development for Postmenopausal osteoporosis in Switzerland (Parenteral)